Galectin Therapeutics reported $93.42M in Loan Capital for its fiscal quarter ending in June of 2024.





Loan Capital Change Date
AbbVie USD 64.53B 5.59B Mar/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Galectin Therapeutics USD 93.42M 9.08M Jun/2024
Gilead Sciences USD 20.86B 1.27B Mar/2026
Immunic USD 0 0 Jun/2024
Incyte USD 28.42M 994K Jun/2026
Merck USD 51.08B 4.41B Jun/2026